Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) PT at $25.00

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has received a consensus recommendation of “Buy” from the seven research firms that are currently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $23.80.

Several research firms have recently weighed in on KALV. Bank of America began coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price objective for the company. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a research report on Friday. They issued an “outperform” rating and a $19.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Finally, TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price target for the company.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 14,400 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $133,344.00. Following the sale, the chief executive officer now owns 266,598 shares of the company’s stock, valued at $2,468,697.48. This represents a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Paul K. Audhya sold 8,077 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $74,793.02. Following the sale, the insider now owns 94,199 shares of the company’s stock, valued at approximately $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,291 shares of company stock worth $304,086 over the last ninety days. Insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. grew its stake in shares of KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after purchasing an additional 2,043 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of KalVista Pharmaceuticals by 10.0% in the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 1,319 shares during the period. Intech Investment Management LLC acquired a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at approximately $126,000. Quest Partners LLC acquired a new position in KalVista Pharmaceuticals in the third quarter valued at $175,000. Finally, The Manufacturers Life Insurance Company boosted its position in KalVista Pharmaceuticals by 27.3% during the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after acquiring an additional 3,314 shares during the last quarter.

KalVista Pharmaceuticals Stock Up 1.6 %

Shares of KALV stock opened at $8.91 on Friday. KalVista Pharmaceuticals has a 12 month low of $7.30 and a 12 month high of $16.88. The firm has a market cap of $440.31 million, a PE ratio of -2.45 and a beta of 0.86. The stock has a 50 day moving average of $8.83 and a 200-day moving average of $10.84.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. As a group, equities analysts predict that KalVista Pharmaceuticals will post -3.56 EPS for the current fiscal year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).